Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03990571 · ClinicalTrials.gov registry record · Phase 2
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
A Phase 2 study of Metastatic Adenoid Cystic Carcinoma and Recurrent Adenoid Cystic Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03990571: Completed Phase 2 study of Metastatic Adenoid Cystic Carcinoma and Recurrent Adenoid Cystic Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT03990571 is a Phase 2 study of Metastatic Adenoid Cystic Carcinoma and Recurrent Adenoid Cystic Carcinoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 45-participant average among 4 other Metastatic Adenoid Cystic Carcinoma trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03990571, a Phase 2 study of Metastatic Adenoid Cystic Carcinoma and Recurrent Adenoid Cystic Carcinoma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well axitinib and avelumab work in treating patients with adenoid cystic carcinoma that has come back or spread to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and avelumab together may help to control adenoid cystic carcinoma.
Primary Outcome
All eligible patients who received at least one cycle of treatment and had at least one restaging image were considered evaluable for the primary end point. Objective response includes complete response (CR) + partial response (PR). Radiographic imaging for tumor assessment was performed at baseline and then every 8 weeks.
Conditions Studied
Interventions
- DRUG Axitinib
- DRUG Avelumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2023-03-20 |
| Phase | Phase 2 |
What the finished NCT03990571 record still lists
NCT03990571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 45-participant average among 4 other Metastatic Adenoid Cystic Carcinoma trials with a reported enrollment target (11% lower).
The record links to 3 conditions, with Metastatic Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Axitinib is the first listed.
NCT03990571 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03990571 about?
NCT03990571 is a clinical study titled "Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma". This phase II trial studies how well axitinib and avelumab work in treating patients with adenoid cystic carcinoma that has come back or spread to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclon...
What is the current status of trial NCT03990571?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-07-22. Estimated completion is 2023-03-20.
What conditions does trial NCT03990571 study?
This clinical trial studies the following conditions: Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma, Progressive Disease.
What interventions are being tested in trial NCT03990571?
The interventions under investigation include: Axitinib (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT03990571?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03990571 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Adenoid Cystic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
RECRUITING · Phase 1
-
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
RECRUITING · Phase 1
-
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
RECRUITING · NA
-
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI